Mr. Alan L. Rubino has a long distinguished career spanning over 30 years at every level of the biopharmaceutical industry.
Prior to joining RenovaCare, Mr. Rubino led a turnaround for Emisphere Technologies, Inc., where he helped to position the company among the leading global oral drug delivery firms. Emisphere’s turnaround was enhanced by a new four molecule collaboration with Novo Nordisk and anchored by the recent FDA approval of Novo Nordisk’s Rybelsus® which incorporated the company’s carrier technology to introduce the first-ever oral GLP-1 therapeutic for the treatment of diabetes.
A major portion of Mr. Rubino’s highly successful career includes his twenty-four years spent at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies. At Roche, he was a corporate officer and member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, drug development project management, human resources, marketing, sales, corporate development, alliance management, and strategic planning .
Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products and achieved major success through the acquisition, marketing, and eventual sale of its herpes labialis drug, Denavir® where the team tripled sales in 18 months and sold then sold the asset to Renaissance Pharmaceuticals, for a multiple of over three times sales and a 49% IRR to investors. Mr. Rubino served before New American Therapeutics, Inc. as the CEO and President of Akrimax Pharmaceuticals, where he and team acquired Tirosint® and NitroMist®, two key NDA approved launch products and Tirosint achieving annual sales of well over $100M.
Mr. Rubino currently serves on the Corporate Boards of Aastrom Biosciences, Genisphere, Inc. and Sanuwave Health, Inc. For the past 20 years, he has served on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. In addition, he has also been a long-time Board Member of both BioNJ and the Healthcare Institute of NJ (HINJ). Mr. Rubino holds a B.A. in economics from Rutgers University along with a full minor in biology and chemistry. He also attended multiple executive education courses at Harvard Business School and the University of Lausanne in Switzerland.
Mr. Rubino also serves as a Board Member on the RenovaCare Corporate Board of Directors.